Denali Therapeutics Inc

+0.91 (+1.75%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.43B
Current PE115.04
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$30.23 Million
Adjusted EPS-$0.46
See more estimates
10-Day MA$52.45
50-Day MA$53.95
200-Day MA$63.80
See more pivots

Denali Therapeutics Inc Stock, NASDAQ:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080
United States of America
Phone: +1.615.866.8548
Number of Employees: 291


Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.